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Imaging studies of ancient human mummies have demonstrated the presence of vascular calciﬁcation that is
consistent with the presence of atherosclerosis. These ﬁndings have stimulated interest in the underlying
biological processes that might impart to humans an inherent predisposition to the development of
atherosclerosis. Clues to these processes may possibly be found in accelerated aging syndromes, such as
Hutchinson-Gilford progeria syndrome (HGPS), an ultra-rare disorder characterized by premature aging
phenotypes, including very aggressive forms of atherosclerosis, occurring in childhood. The genetic defect
in HGPS eventuates in the production of a mutant form of the nuclear structural protein lamin A, called
progerin, which is thought to interfere with normal nuclear functioning. Progerin appears to be expressed
in vascular cells, resulting in vessel wall cell loss and replacement by ﬁbrous tissue, reducing vessel
compliance and promoting calciﬁcation, leading to the vascular dysfunction and atherosclerosis seen in
HGPS. Interestingly, vascular progerin is detectable in lower levels, in an age-related manner, in the
general population, providing the basis for further study of the potential role of abnormal forms of lamin
A in the atherosclerotic process of normal aging.Research Foundation, Na-
tional Endowment for the
Humanities, Paleocardiol-
ogy Foundation (grant #HJ-
50069-12), The National
Bank of Egypt, Siemens,
and Saint Luke’s Hospital
Foundation of Kansas City.
From the *Mission Heritage
Medical Group, St. Joseph
Heritage Health, Mission
Viejo, CA, USA; yDepartment
of Dermatology and Allergy,
Central Institute for Medical
Technology, Technische
Universität München,
Garching, Germany;
zDepartment of Pediatrics,
Hasbro Children’s Hospital,
Warren Alpert Medical
School of Brown University,
Providence, RI, USA; and the
xDepartment of Anesthesia,
Boston Children’s Hospital,
Harvard Medical School,
Boston, MA, USA. Corre-
spondence: M. I. Miyamoto
(miyamoto@cox.net).
GLOBAL HEART
© 2014 World Heart
Federation (Geneva).
Published by Elsevier Ltd.
All rights reserved.
VOL. 9, NO. 2, 2014
ISSN 2211-8160/$36.00.
http://dx.doi.org/10.1016/
j.gheart.2014.04.001During the early stages of the Horus Study [1,2], among
the fundamental questions to be addressed was whether
ancient humans, presumably lacking exposure tomodern risk
factors for the development of atherosclerosis, would show
signs of the disease process by computed tomographic anal-
ysis. An intriguing display in the Egyptian Museum of An-
tiquities in Cairo, describing the Pharaoh Menephtah (ca.
1200 BCE) as having had evidence of atherosclerosis, raised
questions of how atherosclerosis in this ancient royalmummy
was documented, and if accurate, what implications such an
observation might have on our understanding of the disease.
Indeed, the Horus Study demonstrated evidence of the
presence of atherosclerosis in a variety of ancient populations,
with a surprisingly high prevalence and in an age-related
manner [1,2]. These ﬁndings run counter to the prevailing
wisdom that vascular disease is largely a modern scourge,
promoted by factors such as sedentary lifestyles, unhealthy
habits, calorie-rich diets, and their resultant metabolic aber-
rations that proliferated as we humans moved farther away
from our ancient, more basic living circumstances [3].
Given that the mummies examined in this study
represent examples of humans derived from eras without
long-term or intense exposure to modern-day disease-
promoting risk factors, questions then arise as to what
speciﬁc factors might impart to humans an intrinsic risk of
atherosclerosis. Is the aging process itself, indeed, among
the most potent risk factors? If aging is paramount, what
speciﬁc age-related biological processes might contribute to
the development of vascular disease?GLOBAL HEART, VOL. 9, NO. 2, 2014
June 2014: 211-218Syndromes of accelerated aging, very rare diseases char-
acterized by patients developing physiologic aging processes
compressed into short time frames, may provide relevant
clues into vascular disease of normal aging. In a speciﬁc
accelerated aging syndrome, Hutchinson-Gilford progeria
syndrome (HGPS), affected individuals demonstrate a char-
acteristic aging phenotype in childhood, including an
aggressive form of atherosclerosis, with death occurring at a
mean age of 14 years, due to myocardial infarction or stroke,
in the face of normal metabolic parameters [4] and lack of
signiﬁcant family or smoking history [5].
As HGPS patients and many of the ancient humans in
the Horus Study demonstrate atherosclerosis without
intense exposure to conventionally accepted vascular risk
factors, could they together provide insight into the bio-
logical processes that more generally contribute to the
development of age-related vascular disease?THE HORUS STUDY—EVIDENCE OF
ATHEROSCLEROSIS IN ANCIENT HUMANS
Using computed tomographic imaging techniques and
the presence of focal vascular calciﬁcation as a pathogno-
monic sign of atherosclerotic plaque, and leveraging the
sensitivity of computed tomographic imaging to detect
calcium, the Horus Team found radiographic evidence of
atherosclerosis in 4 separate populations of pre-industrial
humans, including groups of hunter-gatherers and
forager-farmers [2] (Fig. 1). Vascular calciﬁcation consistent211
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of 137 mummies (34%) studied. Furthermore, the disease
was found in groups with varying lifestyles, diets, and ge-
netics with great temporal and geographic diversity. Of note,
estimated age at death was found to be a determinant of the
presence and extent of atherosclerosis, with the odds of
increasing atherosclerosis severity increased by nearly 70%
per decade of life (Fig. 2).
These ﬁndings of vascular calciﬁcations in pre-
industrial humans raise fundamental questions about the
nature of atherosclerosis, and whether humans as a species
possess an underlying, age-related predisposition to the
disease, independent of the effects of conventionally
accepted modern vascular risk factors. Potential factors
promoting the development of atherosclerosis in at least
some populations of ancient humans include chronic in-
fections and inﬂammation, as well as exposure to smoke
from indoor cooking ﬁres [2].
If ancient human mummies represent a model of age-
related atherosclerosis occurring in the absence of intense
exposure to “modern” vascular risk factors, then perhaps
an examination of features of HGPS may provide yet more
important insights into some of the relevant age-dependent
biological mediators involved.HUTCHINSON-GILFORD PROGERIA SYNDROME—
GENETICS AND ACCELERATED VASCULAR AGING
Due in part to its extreme rarity (1 in 4 million live births),
HGPS was not described until the late 1800s by Jonathan
Hutchinson and Hastings Gilford [6e8]. Gilford recog-
nized that many of the features of the disease involved
normative aging processes that, strikingly, appeared in
young children. The condition is characterized by pheno-
typic features developing in childhood that are generallyFIGURE 1. Atherosclerosis in an ancient Egyptian mummy an
image of the mummy of a princess who lived during the Secon
and iliac arteries and aorta, indicating this person had diffus
modern Egyptian patient showing similar calciﬁcations in the
right coronary artery. Reproduced with permission from: Tho
across 4000 years of human history: the Horus study of four afound in the elderly, including alopecia, subcutaneous fat
loss, decreased bone density, and a dramatic form of pre-
mature accelerated atherosclerosis (Fig. 3).
In a major milestone in the understanding of the dis-
ease, the genetic abnormality that underlies HGPS was
elucidated, in 2003 [9,10], as a sporadic, autosomal
dominant, silent mutation in the LMNA gene. The LMNA
gene codes for lamins A and C, major structural proteins of
the nuclear lamina, a protein scaffolding network under-
lying the inner nuclear membrane [11]. In about 90% of
HGPS patients, a C/ T mutation occurs at position 1,824
of codon 608 of exon 11; the other 10% of patients possess
mutations within the intron 11 splice donor sequence and
produce the same aberrant disease-causing protein [9].
In all cases, activation of a cryptic splice donor site 150
base pairs upstream of the 30 end of exon 11 favors alter-
native splicing of the LMNA messenger ribonucleic acid,
leading to production of a truncated mutant prelamin A,
called progerin, with a 50 amino acid deletion near its
C-terminus. Progerin acts in a dominant negative pattern; it
is the presence of progerin, which causes disease [12].
Both wild-type lamin A and mutant progerin undergo
a series of post-translational modiﬁcations, including the
addition of a farnesyl group to the C-terminal end, which is
thought to aid in the targeting of these proteins to the
nuclear envelope [13]. Mature lamin A is then derived from
cleavage of the C-terminal 15 amino acids, including the
farnesyl group, by the metalloproteinase FACE1/Zmpste24
[14] (Fig. 4A [15]). However, in HGPS, progerin is missing
its FACE1/Zmpste24 cleavage site due to this 50 amino
acid deletion (Fig. 4B); it therefore retains its farnesyl
group, preventing the movement of the mutant protein
from the nuclear envelope to the nucleoplasm for protein
degradation [9]. It stays intercalated within the nuclear
membrane via hydrophobic interaction with lipids and/ord a modern Egyptian patient. (A) Computed tomographic
d Intermediate Period shows calciﬁcations in the coronary
e atherosclerosis. (B) Computed tomographic scan from a
coronary and iliac arteries. LCA, left coronary artery; RCA,
mpson RC, Allam AH, Lombardi GP, et al. Atherosclerosis
ncient populations. Lancet 2013;381:1211e22 [2].
GLOBAL HEART, VOL. 9, NO. 2, 2014
June 2014: 211-218
FIGURE 3. Photograph of a 17-year-old girl with
Hutchinson-Gilford progeria syndrome. Courtesy of The
Progeria Research Foundation.
A B
FIGURE 2. Age-related prevalence and extent of atherosclerosis in pre-industrial humans, in the Horus Study. (A)
Mean age of death versus severity of atherosclerosis. (B) Frequency of atherosclerosis by age group. Reproduced with
permission from: Thompson RC, Allam AH, Lombardi GP, et al. Atherosclerosis across 4000 years of human history: the
Horus study of four ancient populations. Lancet 2013;381:1211-22 [2].
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rupting the overall nuclear laminar organization and
structure. Nuclei from progerin-positive cells demonstrate
a characteristic abnormal, blebbed appearance as well as
other consistent signaling abnormalities (Figs. 5 [16] and
6). Because the nuclear lamina plays important roles in
gene transcription and regulation, deoxyribonucleic acid
(DNA) repair, and heterochromatin organization [17],
progerin-induced effects on the nuclear lamina appear to
underlie the cellular abnormalities observed in HGPS,
including premature cellular senescence.
As part of the HGPS disease process, affected in-
dividuals universally demonstrate an aggressive vasculop-
athy, resulting in death at a young age due to myocardial
infarction or stroke. The vasculopathy is characterized by
loss of medial smooth muscle cells, adventitial thickening,
intimal calciﬁcation, and atherosclerotic plaquing in the
great vessels, small arteries, and arterioles [18]. Many, but
not all, of the observed features of these vascular abnor-
malities share similarities with ﬁndings seen in senile
atherosclerosis. Some features, such as inﬂammation and
intimal lipid deposition, were not observed in an early
description of HGPS vessels, although the subjects of these
early reports were not genetically conﬁrmed [18].
More recently, coronary arterial ﬁndings in 2 HGPS
patients (ages 9.9 and 14 years) who died of myocardial
infarction included dense ﬁbrosis and medial thinning, with
some lesions demonstrating a necrotic core and foci of
chronic inﬂammation [19]. Coronary lesions were rich in
collagen and proteoglycans and displayed large regions of
calciﬁcation, similar to ﬁbrocalciﬁc atheroma (Fig. 7). Acute
plaque rupture and thrombosis was not observed, but there
was evidence of healed plaque rupture, suggesting a contri-
bution of this process to the development of progressive,
ﬂow-limiting stenoses. In addition, thickening and calciﬁca-
tion of the cardiac valves were observed, with high progerin
expression present in valvular mesenchymal cells [19]. There213
A B
FIGURE 4. Prelamin A processing. (A) Normal prelamin A processing, with mature lamin A derived from the cleavage of
the C-terminal 15 amino acids, including the farnesyl group. (B) Production of mutant lamin A (progerin), due to loss of
the cleavage site, resulting in retention of the farnesyl group. Reproduced with permission from: Gordon LB, Brown WT,
Rothman FG. LMNA and the Hutchinson-Gilford progeria syndrome and associated laminopathies. In: Epstein CJ,
Erickson RP, Wynshaw-Boris A, editors. Inborn Errors of Development: The Molecular Basis of Clinical Disorders of
Morphogenesis. 3rd edition. New York, NY: Oxford University Press [15].
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214was thickening of the left ventricular endocardium, with
progerin found at increasing levels in endocardial ﬁbroblasts.
ABNORMAL VASCULAR FUNCTION IN HGPS
It has been postulated that loss of medial vascular smooth
muscle cells and replacement by ﬁbrous elements results in aFIGURE 5. Nuclear blebbing and presence of progerin in Hu
nuclei stained with anti-lamin A antibody: (A) Hutchinson-Gilfo
The Hutchinson-Gilford progeria syndrome ﬁbroblast demons
ular, blebbed appearance. Reproduced with permission from
Gilford progeria syndrome: insights into normal aging. In: Fill
Textbook of Geriatric Medicine and Gerontology. 7th edition.loss of vessel compliance, increased arterial stiffness, and
vessel wall injury. Consistent with this, abnormalities in
indices of vascular function have been demonstrated in
HGPS patients [20]. Patients as young as 3 years of age (mean
age 7.4 3.4 years) were found to have measurable vascular
abnormalities, including elevated carotid-femoral pulse wavetchinson-Gilford progeria syndrome and aging. Fibroblast
rd progeria syndrome ﬁbroblast, (B) normal aged ﬁbroblast.
trates marked morphological abnormalities, with an irreg-
: Gordon LB. The premature aging syndrome Hutchinson-
et HM, Rockwood K, Woodhouse K, editors. Brocklehurst’s
New York, NY: Saunders Elsevier; 2009. p. 66e72 [16].
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FIGURE 6. Nuclear abnormalities in Hutchinson-Gilford
progeria syndrome. Low magniﬁcation transmission
electron microscopic image of an HGPS nucleus showing
several herniations (arrows). The altered nuclear structure
is due to progerin-induced abnormalities of the nuclear
envelope and lamina, the protein scaffolding network
underlying the inner layer of the nuclear envelope. Note
that heterochromatin is barely visible on the section. Loss
of heterochromatin is one of the hallmarks of
Hutchinson-Gilford progeria syndrome.
FIGURE 7. Histological similarity of coronary artery
atherosclerotic plaque in Hutchinson-Gilford progeria
syndrome and adult coronary artery disease. ca, calciﬁ-
cation; nc, necrotic core. Reproduced with permission
from: Olive M, Harten I, Mitchell R, et al. Cardiovascular
pathology in Hutchinson-Gilford progeria: correlation
with the vascular pathology of aging. Arterioscler Thromb
Vasc Biol 2010;30:2301e9 [19].
gREVIEWjvelocity, increased intima-media and adventitia echodensity
(increased vascular stiffening), abnormal ankle-brachial
indices, and elevated mean distal internal carotid artery
ﬂow velocity (signs of arterial occlusive disease). The
equivalent pulse wave velocity for the group mean in HGPS
patients was equal to that of a normal 60-year-old [21].
Notably, many of these vascular ﬁndings are
commonly found in normal human aging. But in the case
of HGPS, they occur in children without prolonged
exposure to conventional vascular risk factors, with normal
cholesterol and high-sensitivity C-reactive protein levels
[4], lack of signiﬁcant family history, and no smoking
history, regardless of sex or ethnicity [5].
These observations have stimulated great interest in
HGPS as a model for vascular aging and a possible,
important role for altered lamin A expression in the
development of arterial pathology in non-HGPS settings.
PROGERIN EXPRESSION IN NORMAL HUMAN
AGING
The altered form of lamin A is detectable in cells and tis-
sues from healthy, non-HGPS individuals. This important
observation has further intensiﬁed interest in the possible
role of progerin in age-related vascular disease.
The production of progerin in normal cells is thought
to be due to sporadic use of the unmutated cryptic HGPSGLOBAL HEART, VOL. 9, NO. 2, 2014
June 2014: 211-218splice site. Progerin has been detected in skin ﬁbroblast cell
lines from healthy, elderly individuals, at levels approxi-
mately 50-fold less than those observed in HGPS cells, but
nevertheless accompanied by observable nuclear defects and
altered nuclear localization of wild-type lamin A, similar to
that seen in HGPS cells [22]. The in vivo correlate shows that
progerin is present in an age-dependent manner in normal
aging human skin biopsies [23]. Furthermore, progerin
expression has been detected in coronary arteries in the
general population, in an age-related manner, using immu-
nohistochemical techniques [19]. In an examination of
coronary arteries from 29 patients ranging in age from 1
month to 97 years, progerin staining with an antiprogerin
antibody was observed in the adventitia, as well as the media
and atherosclerotic plaque (although at lower levels than215
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216those in the adventitia) (Fig. 8). The progerin staining rate
increased from 1 per 1,000 cells at 1 month of age to 19.66
per 1,000 cells at age 97 years. The progerin-positive cell
types were thought to be adventitial ﬁbroblasts or, less likely,
immune cells that accumulate in response to cell death.POSSIBLE MECHANISMS OF PROGERIN-INDUCED
VASCULAR DISEASE
Although the mechanisms by which progerin ultimately
leads to the accelerated degree of vascular disease in HGPS,
and perhaps to age-related atherosclerosis, remain un-
known, several hypotheses, based on both pre-clinical and
clinical data, can be proposed. In one hypothesis, the nu-
clear abnormalities and dysregulation of the function of the
nuclear lamina affect gene expression [24] and DNA repair
[25]; interfere with mitosis, causing abnormal chromosome
segregation and binucleation [26]; and interact with up-
stream telomere dysfunction [27] to induce cellular
senescence, resulting in the loss of vascular smooth muscle
cells and/or adventitial ﬁbroblast dysfunction. Cell death
promotes extracellular matrix accumulation as seen in theFIGURE 8. Progerin expression in adult coronary artery d
media. (B) Blue: 40,6-diamidino-2-phenylindole ﬂuorescent s
progerin and 40,6-diamidino-2-phenylindole, demonstrating p
atherosclerotic plaque. Staining performed in a coronary artthick, dense vascular walls in HGPS. Collectively these
factors would result in adverse effects on vessel wall
compliance. Progerin-related DNA damage may also pro-
mote vascular calciﬁcation by inducing a senescence-
associated secretory phenotype, leading to osteogenic
differentiation of vascular smooth muscle cells, as well as a
reduction in the production and accumulation of extra-
cellular pyrophosphate, which is normally a potent in-
hibitor of vascular calciﬁcation [28,29].
Atherosclerotic changes associated with laminopathies
other than HGPS further support a potential pivotal role for
abnormal lamin A in vascular disease. Altogether, there are
>180 known mutations in nuclear lamin genes, associated
with 13 known diseases, some of which are associated with
premature vascular disease [11,30,31]. Besides HGPS, for
example, premature atherosclerosis is observed in familial
partial lipodystrophy, Dunnigan type (LMNA missense mu-
tations in exons 8 and 11), and atypical Werner syndrome (3
autosomal-dominant LMNA mutations). These diseases are
caused not by progerin, but by other abnormal forms of
prelamin A. These observations point to the potential role of
such abnormal forms of lamin A in atherosclerosis.isease. (A) Red: antiprogerin antibody staining in vessel
tain of deoxyribonucleic acid. (C) Merged signal of anti-
rogerin-positive nuclei. (D) Photomicrograph of coronary
ery from a 31-year-old.
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A repeating cycle of vascular cell damage, perhaps
promoted by oxidative and mechanical stress, leading to a
cascade of events resulting in increased vascular stiffness
and plaque formation, placing the vasculature at risk for
further oxidative and mechanical damage, may underlie the
accelerated vasculopathy observed in HGPS, a subset of
non-progerin-producing laminopathies, and possibly,
more generally, some proportion of age-related vascular
disease. Further elucidation of the speciﬁc events involved
in such a process may improve the understanding of the
fundamental underpinnings of atherosclerosis.FIGURE 9. A proposed paradigm of atherosclerosis in
antiquity, accelerated aging syndromes, and normative
aging. The progressive, age-related nature of atheroscle-
rosis may be in part related to expression of abnormal
lamin A. Other factors such as biological regulators, in-
fections, modern vascular risk factors, and genetic in-
ﬂuences may modulate the rate of progression of
atherosclerosis, determining the point at which clinical
disease becomes manifest. Treatments that mitigate
these factors may retard the rate of atherosclerosis
development, preventing or deferring the onset of
symptomatic disease stages. HGPS, Hutchinson-Gilford
progeria syndrome.IMPLICATIONS, A POSSIBLE PARADIGM OF
ATHEROSCLEROSIS, AND FUTURE DIRECTIONS
The observations of severe vascular disease occurring at a
very young age in HGPS patients and the detection of
progerin in non-HGPS coronary artery disease together
suggest that at least a part of an inherent human predis-
position to atherosclerosis may be attributable to the
vascular effects of progerin and/or other abnormal lamin A
forms. That such a basic human propensity to the disease
exists should not be surprising, perhaps. Clinically, the
occurrence of serious disease states related to atheroscle-
rosis, such as acute coronary and stroke syndromes, is not
uncommonly observed in modern patients lacking obvious
vascular risk factors. In explaining these patients’ situa-
tions, medical providers often vaguely cite complex genetic
risk, “bad luck,” or other, unrecognized factors. It is
tempting to speculate that age-related vascular progerin
production may be a speciﬁc, possibly even major,
example of such factors.
A central role for abnormal lamin A in atherosclerosis
associated with certain laminopathies, and possibly normal
aging, has stimulated interest in novel therapeutic targets.
For example, protein farnesyltransferase inhibitors, which
inhibit farnesylation of prelamin A, thereby reducing the
toxicity of mutant lamin A, are being studied as potential
treatments to ameliorate some of the devastating manifes-
tations of HGPS. One of these inhibitors, lonafarnib, has
demonstrated decreases in arterial pulse wave velocity and
carotid artery echodensity, indices of vascular stiffness, in
children with HGPS [32]. Whether these therapies may
also be effective in preventing or reducing the burden of
age-associated atherosclerosis remains the subject of very
early, but intriguing, speculation.
From these considerations, a proposed paradigm of
human atherosclerosis may be offered (Fig. 9): 1) The
development of atherosclerosis in humans is an inexorable
process, perhaps in part related to progressive, age-related
progerin and/or other abnormal lamin A expression and
accumulation. 2) Atherosclerosis remains clinically silent,
until it reaches a threshold burden of disease (ﬂow-limiting
stenosis) and/or disease activity (plaque rupture and
thrombosis). 3) The background rate of the development
of atherosclerosis may be accelerated to varying degrees by
multiple factors, many of which may be interrelated,GLOBAL HEART, VOL. 9, NO. 2, 2014
June 2014: 211-218including modern vascular risk factors (e.g., sedentary
lifestyles, obesity, tobacco use, hypertension, metabolic
derangements), chronic infections/inﬂammation (perhaps
particularly relevant to ancient peoples), and genetic pre-
dispositions that have been found to be associated with
higher risk of clinical vascular disease. 4) Effective risk
factor management and medical therapies may retard the
progression of atherosclerosis, reducing or delaying the
risk of reaching a threshold level of disease or disease ac-
tivity associated with clinical disease manifestations. It
should be noted that the evidence of atherosclerosis in
ancient humans seen in the Horus Study was not proof of
the presence of clinical, symptomatic disease. However,
widespread vascular calciﬁcation in multiple beds was
observed in some mummies. In addition, some ancient
Egyptian hieroglyphic papyri describe symptoms consis-
tent with angina, acute myocardial infarction, and
congestive heart failure [33,34].
Future study of the regulators of progerin expression
in the general population will be important to examine
possible environmental, infectious, and genetic inﬂuences,
which may help to unify certain seemingly disparate
components of the disease process. In non-HGPS skin ﬁ-
broblasts, for example, progerin expression has recently
been found to be stimulated by exposure to long wave
ultraviolet light [35]. It is possible that other cellular
stressors such as oxidative damage and mechanical stress
may have similar effects on vascular cells. It is interesting to
note that HGPS children with the exact same mutation may
express disease progression at very different rates, with217
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218some dying of vascular disease at age 7 years and others at
age 17, suggesting that modifying biological factors
involving speciﬁc regulatory proteins inﬂuence the amount
of progerin production or its damaging effects, and, hence,
the rate of progression of vasculopathy. Further study of
these modifying factors may shed further light on the
atherosclerotic process in normal aging and provide po-
tential therapeutic targets.
The Horus Team plans to probe for the presence of
progerin in ancient human mummy tissue samples, and, if
detectable, to evaluate possible correlations of age and
protein expression, as well as progerin detection and
radiographic signs of atherosclerosis.
SUMMARY
It is perhaps ironic that humans living thousands of years
ago, as well as modern children suffering an extremely rare
genetic disease may together help to shed light on some of
the fundamental processes that underlie one of the most
common diseases of modern humans. If, from such in-
vestigations, our understanding of vascular disease is
signiﬁcantly advanced, perhaps forming the basis for novel
preventive treatments, we will owe a debt of gratitude to
both the ancients and those with HGPS.REFERENCES
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